News and Trends 21 Oct 2016 Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease Forget about Madrid and Barcelona, the island of Mallorca has one of the hottest Biotechs in Spain: Sanifit is targeting calciphylaxis, an orphan disease that affects the huge dialysis market. Sanifit received the highest financing round in Spain last year (and probably ever) with €36.6M in series C. With this money, the company is advancing its candidate SNF472 in […] October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 German Record-deal Antiviral drug Succeeds in Phase III AiCuris’ Letermovir succeeds in Phase III after being licensed to MSD in a record €442.5M deal. It acts on a novel CMV target to treat bone marrow transplant infections. AiCuris is a spin-out company from Bayer, Germany’s biggest Pharma, that focuses on developing drugs for infectious diseases. The company licensed its candidate Letermovir (AIC246) to MSD (Merck & co.) in 2012, making it the […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged? Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2016 The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies. In May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target […] October 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2016 And the highest funding in Europe this year goes to… Antibody-Drug Conjugates! AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest […] October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016 This New Biotech wants to Regrow Neurons to cure Parkinson’s Mavalon Therapeutics will develop a drug candidate for Parkinson’s that can stop the disease progression by activating the growth of dying neurons. Mavalon Therapeutics, born today in the UK, will be entirely dedicated to the development of a drug candidate to stop the progression of Parkinson’s. Domain Therapeutics has created this new company with a €9M investment […] October 18, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016 €4M Grant for a Cancer Vaccine that could Bench its Competitors Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […] October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016 How can Cultured Meat solve World Hunger and Global Warming? What is ‘cultured meat’ and how can it address the most pressing global problems? Let us introduce you to some of the brilliant minds behind it. The world’s population is predicted to reach almost 10 billion by 2050, and we don’t have the resources to feed all of them… yet. The meat industry currently uses 70% of […] October 18, 2016 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2016 Meet the First Biotech to Jump on Autophagy After This Years’ Nobel Prize Just after the Nobel Prize was awarded to the study of autophagy, PhoreMost announces a collaboration to target the process in neurodegenerative diseases. PhoreMost is a drug discovery company that focuses on finding ‘undruggable’ targets, such as the KRAS cancer gene. Now, the company has announced a collaboration with the University of Cambridge to start working […] October 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2016 This Start-up sells Cheap 3D-printed Microscopes for Bacterial testing What if you could print your own microscope to save money? WaterScope has designed a 3D-printed microscope for rapid water testing in the field on a budget. WaterScope is a spin-out from the University of Cambridge that 3D prints microscopes and sells them to anyone that requires low-cost equipment for their project or start-up. The funds will […] October 13, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2016 Transgene teams up with big Players against HPV Head and Neck Cancer Transgene is partnering with Merck and Pfizer to develop a combined therapy for head and neck cancer squamous cell carcinoma (HNSCC) caused by human papiloma virus (HPV) infections. A successful outcome will let the team access a €2B market niche. Transgene has been struggling for a while: last year it had to fire 40% of its workforce […] October 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2016 Will Aprea live up to the Hype of its €46M fundraising? Aprea raised a huge €46M for a first-in-class drug that targets the deadliest form of ovarian cancer. The company just started Phase II trials after positive results from Phase I. But will it be able to outperform all its competitors? Aprea is a spin-out company from the Karolinska Development, the portfolio company of the Institute, in Sweden. It became […] October 12, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email